Cognitive and behaviour profiles of children with mucopolysaccharidosis Type II

被引:7
|
作者
Crowe, Louise [1 ,2 ,3 ]
Yaplito-Lee, Joy [4 ]
Anderson, Vicki [1 ,2 ,3 ]
Peters, Heidi [4 ]
机构
[1] Royal Childrens Hosp, Murdoch Childrens Res Inst, Clin Sci, Melbourne, Vic, Australia
[2] Royal Childrens Hosp, Psychol Dept, Melbourne, Vic, Australia
[3] Univ Melbourne, Psychol Sci, Melbourne, Vic, Australia
[4] Royal Childrens Hosp, Dept Metab Med, Melbourne, Vic, Australia
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
Children; cognition; Hunter syndrome; mucopolysaccharidosis Type II; REPLACEMENT THERAPY; HUNTERS SYNDROME; MILD; ABNORMALITIES; CHILDHOOD; OUTCOMES; DISEASE; ADULTS;
D O I
10.1080/02643294.2017.1401530
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
Mucopolysaccharidosis Type II (MPS II) or Hunter Syndrome is a rare X-linked condition, due to a defect in a lysosomal enzyme involved in the breakdown of glycosaminoglycans. It is a progressive condition with worsening over time; however, symptom severity and progression rates vary. Normal intellectual function has been reported in males with mild MPS II but few studies are available that provide comprehensive cognitive profiles. Enzyme replacement therapy (ERT) can stabilize physical symptoms and has become standard treatment. Whether ERT can influence cognition is currently unknown. Considering this, we conducted cognitive, fine motor, and behavioural assessments with three males (7; 6-12; 1 years) with mild MPS II before and after ERT. Generally, cognition, fine motor skills, and behaviour were in the normal range; however, specific deficits in attention and executive function were identified. Following ERT, some memory improvements were seen. Executive deficits remained, and processing speed declined over time.
引用
收藏
页码:347 / 356
页数:10
相关论文
共 50 条
  • [21] Mucopolysaccharidosis Type II: A Kenyan Case Series
    Mungai, L. N. Wainaina
    Njeru, C. M.
    Nyamai, L. A.
    Maina, M.
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2021, 2021
  • [22] The characterization of mouse model of mucopolysaccharidosis type II
    Kinoshita, Masafumi
    Morimoto, Hideto
    Yoden, Eiji
    MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S64 - S64
  • [23] Mucopolysaccharidosis type II: an update on mutation spectrum
    Froissart, Roseline
    Da Silva, Isabel Moreira
    Maire, Irene
    ACTA PAEDIATRICA, 2007, 96 : 71 - 77
  • [24] MUCOPOLYSACCHARIDOSIS TYPE-II (HUNTER SYNDROME)
    LAMBOTTE, C
    WINANT, R
    LOEB, H
    TONDEUR, M
    VAMOS, E
    VANHOOF, F
    NEUFELD, E
    ARCHIVES FRANCAISES DE PEDIATRIE, 1971, 28 (05): : 568 - &
  • [25] Longitudinal bronchoscopy findings in children with mucopolysaccharidosis II (MPS II)
    Muhlebach, Marianne
    Muenzer, Joseph
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [26] A molecular genetics view on Mucopolysaccharidosis Type II
    Verma, Shalja
    Pantoom, Supansa
    Petters, Janine
    Pandey, Anand Kumar
    Hermann, Andreas
    Lukas, Jan
    MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2021, 788
  • [27] Mucopolysaccharidosis type II - genotype/phenotype aspects
    Froissart, R
    da Silva, IM
    Guffon, N
    Bozon, D
    Maire, I
    ACTA PAEDIATRICA, 2002, 91 : 82 - 87
  • [28] Mucopolysaccharidosis Type II, Hunter's Syndrome
    Tylki-Szymanska, Anna
    PEDIATRIC ENDOCRINOLOGY REVIEWS PER, 2014, 12 : 107 - 113
  • [29] Enzyme replacement therapy in mucopolysaccharidosis type II
    Castorina, M.
    Antuzzi, D.
    Zampetti, A.
    Ricci, R.
    ACTA PAEDIATRICA, 2008, 97 : 101 - 101
  • [30] Expanding the phenotype of mucopolysaccharidosis type II retinopathy
    Kowalski, Tanya
    Ruddle, Jonathan B.
    de Jong, Gerard
    Mack, Heather G.
    OPHTHALMIC GENETICS, 2021, 42 (05) : 631 - 636